Ion Beam Applications S.A. (0GZK)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 16.22 |
|---|---|
| 52-week range | 9.81 – 17.72 |
| Return, 1 month / 3 months | +4.6% / +0.4% |
| Return, 1 year / 3 years | +47.3% / +80.9% |
| Trend | Uptrend |
| RSI (14) | 57 |
| Volatility (1 year) | 31.0% |
| Worst drawdown (1 year) | -21.1% |
| Average daily value traded | 0.02M EUR |
| Dividend yield | 1.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ion Beam Applications S.A. is a Belgian company that designs and builds proton therapy systems used by hospitals and cancer treatment centres to treat tumours. It also supplies particle accelerators, equipment for producing medical radioisotopes, and related services for healthcare and industrial customers. The company is based in Louvain-la-Neuve, Belgium, and works with hospitals and research institutions in many countries.
On this site Ion Beam Applications S.A. appears as a stock on the London Exchange (UK), code 0GZK, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ion Beam Applications S.A. (0GZK) trades on the London Exchange in UK. It last closed at EUR 16.22 on 21 October 2026.
Its price-based Market X-Ray is 58 out of 100 (a fair price profile), ranking 1,556 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 47.3% and over the last three months it rose 0.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 66 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 6.3% | ||
| From 52-week high | -7.8% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 0.4% | ||
| 6-month return | 15.8% | ||
| 12-month return, skipping the last month | 40.7% | ||
| Stability (higher is calmer) | 65 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 31.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.1% | ||
| Liquidity | 17 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M EUR | ||
| Zero-volume days | 6.7% | ||
| Income | 45 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.1% | ||
| Years with dividends | 5 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.1% |
|---|---|
| 1 month | +4.6% |
| 3 months | +0.4% |
| 6 months | +15.8% |
| 1 year | +47.3% |
| 3 years | +80.9% |
| 5 years | +0.8% |
Signals
| 50-day / 200-day average | 15.74 / 15.25 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.42 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Jun 2026 | EUR 0.1750 |
| 18 Jun 2025 | EUR 0.1680 |
| 19 Jun 2024 | EUR 0.1190 |
| 29 Jun 2023 | EUR 0.1470 |
| 29 Jun 2022 | EUR 0.1330 |
| 21 Jun 2021 | EUR 0.1400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.